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Abstract 
The calculation of Surface Site Interaction Points for cocrystal computational screens in combination with 
efficient experimental cocrystallization techniques has been applied successfully to several drug 
compounds. The basics of this combined approach are briefly reviewed in this communication. 
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The search for new cocrystals of APIs can be very expensive in terms of time and economical resources 
since the number of potential coformers available with suitable toxicity profiles is huge. Thus, there is a 
real need in the pharmaceutical industry to optimize screening methodologies, because cocrystals offer 
solutions to some of the drawbacks inherent to many drug candidates, such as low solubility and 
bioavailability. Historically, the supramolecular synthon approach has been the paradigm of crystal 
engineering for the design of new multicomponent crystals based on strong intermolecular interactions [1]. 
Although very limited in the scope for efficiently locating new coformers, supramolecular synthons are the 
basis for understanding the formation of a cocrystal. More recently other approaches have been 
developed for predicting the outcome of cocrystallization experiments. The Hansen solubility parameter 
[2] has been investigated to guide cocrystal screening. Statistical analyses of the properties of compounds 
known to form cocrystals show promise. For example, Fabián showed that cocrystals are usually formed by 
molecules of similar shapes and polarities [3], and the hydrogen bond propensity tool developed by the 
Cambridge Crystallographic Data Centre has been used to predict the cocrystallization of several APIs [4]. 
Computational methods have also been applied to the cocrystal problem. A high-level DFT study of 350 
organic cocrystals concluded that the formulation of general rules to guide cocrystal formation remains 
difficult [5].  
We have developed a fast computational method to screen large libraries of coformers [6]. The 
approach uses Hunter's hydrogen bond parameters ( and ) [7] to predict the formation of intermolecular 
interactions in crystals and is based on the principle that the crystal structure of an organic compound is 
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controlled by a hierarchical organisation of functional group interactions. Thus, the energy of a solid form 
(E) can be calculated by pairing the best H-bond donor with the best H-bond acceptor, the second best H-
bond donor with the second best H-bond acceptor, and so on, until all of the interaction sites (i,j) are 
satisfied (Eq. 1).  
i j
ij
E       (1) 
The difference between the interaction site pairing energies of the cocrystal (Ecc) and the two 
components (E1 and E2) is related to the cocrystallization probability (Eq. 2). 
1 2ccE E nE mE     (2) 
where n and m refer to the cocrystal stoichiometry. 
The method is based on assumptions that ignore all geometrical aspects of crystal packing: (a) all 
potential interactions in the crystalline solid are established (b) all H-bond sites on the surface of a 
molecule are independent and free to interact with any other site in the solid, (c) steric constraints on 
contacts are not considered, (d) cooperativity between sites is ignored. The consequence of these 
approximations is that the method offers a solution to the problem of rapid virtual screening of large 
compound libraries. The method was initially calibrated by performing calculations on two APIs with the 
highest number of reported experimental cocrystals (caffeine and carbamazepine) and a list of nearly 1,000 
potential coformers, providing a validation of the relationship between the value of ΔE and the probability 
of cocrystal formation (Fig.1). 
 
Figure 1. Recall plots for the prediction of 1:1 cocrystals of caffeine (a) and carbamazepine (b) with 849 and 
860 potential coformers respectively. H is the fraction of total hits found plotted as function of the fraction of 
compounds screened (N). The line (r) represents probability of finding a hit as the result of random chance. (c) 
Relationship between the probability of obtaining a cocrystal, P, and the calculated cocrystal energy, .  
 
In addition, a set of validations was conducted with cocrystal screens of nine APIs from the literature 
(diclofenac, piracetam, pyrazine carboxamide, acetazolamide, indomethacin, furosemide, nalidixic acid, 
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paracetamol and a drug candidate) that had reported both successful and unsuccessful coformers, and in 
most cases, calculations reproduced the experimental results [8]. The method has been further applied in 
combination with experimental screening techniques to optimize the search for new cocrystals with 
improved physicochemical properties of APIs, such as nalidixic acid [9] spironolactone, griseofulvin [10], 
zafirlukast [11], sildenafil [12,13] and a novel inhaled JAK-STAT inhibitor [14]. 
 
Figure 2. Drug compounds tested in combined virtual/experimental cocrystal screens 
Virtual cocrystal screening for coformer selection is just part of the more complicated procedure of 
cocrystal investigation in the pharmaceutical industry. Thus, other pre-screening techniques must be 
applied prior to the experimental search for new cocrystals in order to reduce time and optimize resources. 
For instance, solubility prediction can also be conducted if an increase/decrease in solubility is a 
requirement for the formulation [15], and the safety/toxicity profile of every potential coformer must be 
assessed using databases or in silico prediction [16]. Finally, once all the computational work is done, 
information about the solubility of the API and the chosen coformers in the organic solvents used for 
crystallisation and about the presence of polymorphism/solvatomorphism is necessary. This information is 
essential for selection of the experimental conditions which will allow the most extensive and efficient 
exploration of the cocrystal landscape. In summary, the use of computational approaches together with 
experimental screening methodologies, if combined efficiently, can reduce the time and cost of the 
development of a new cocrystal formulation.    
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